-
FDA approves Ripretinib for treatment of advanced gastrointestinal mesotypes! Reding Pharma Holds China Interests
Time of Update: 2020-05-29
On May 15, Deciphera Pharmaceuticals announced that the FDA had approved the listing of its Qinlock (ripretinib) for the treatment of patients with advanced gastrointestinal interthelemic sylloma (
-
Radiology: Convolution-based neural network software can improve the detection rate of malignant tumors in chest
Time of Update: 2020-05-29
Background the additional benefits of detecting malignant lung tumor nodules in chest syllomas using deep convolutional neural network (DCNN) software are yet to be verified by multicenter studie
-
NEJM: Olapani Treats Metastatic Drug-resistant Prostate Cancer
Time of Update: 2020-05-29
Multiple cancers are associated with polysephonic (diphosphate adenosine-ribose) polymerase (PARP), and researchers recently looked at the effectiveness of Orapani's treatment for prostate cancer
-
A major breakthrough in liver cancer in ten years! The first-line treatment of Roche Tecentriq and Avastin (Special Sanqi and Anvidin) significantly extends the total survival!
Time of Update: 2020-05-28
May 26, 2020 / Biovalley BIOON/ -- Recently, the evaluation of Roche's anti-PD-L1 therapy Tecentriq (Special, generic name: atezolizumab, Atezolizumab) united avastin (Anvetin), generic name: bevac
-
Breakthrough! Immunotherapy combination significantly prolongs the survival of patients with bile duct cancer!
Time of Update: 2020-05-28
May 23, 2020 / Biogroin BIOON /-- A randomized, multicenter combination of immunotherapy and targeted therapy has improved cancer control in some rare and fatal types of gastrointestinal cancer, kn
-
Lancet Clinical Discovery! One week of radiotherapy is effective for breast cancer patients! It's equivalent to three weeks of radiotherapy!
Time of Update: 2020-05-28
May 22, 2020 / BioValley BIOON/-- A study found that for patients with breast cancer early after surgery, a week of radiation treatment at a shorter but larger daily dose is as safe and effective
-
Lung cancer personalized medicine! AstraZeneca has partnered with ArcherDX to develop an individualized cancer detection method to identify small residuals in lung cancer!
Time of Update: 2020-05-28
May 26, 2020 / Biovalley BIOON/-- AstraZeneca recently partnered with ArcherDX, a genomics analysis firm focused on precision oncology , to detect micro-residual disease (minimaldisease, MRD) in
-
CAR-T Killer! CD19 target new Fc-optimized immuno-enhanced monotafasitamab EU entry review, the treatment of B cell tumor efficacy is strong!
Time of Update: 2020-05-28
May 25, 2020 / Biovalley BIOON/ -- MorphoSys and Incyte recently jointly announced that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) of Tafasitamab
-
Cell Cancer: Scientists successfully transform autoimmune drugs into anti-cancer drugs
Time of Update: 2020-05-28
May 25, 2020 /PRNewswire/ -- Scientists from the Antibody and Vaccine Team at the University of Southampton have recently discovered a way to convert previously developed antibody drugs for the trea
-
MAJOR ADVANCES IN NEJM: BREAST CANCER DRUGS TO TREAT PROSTATE CANCER ARE MORE EFFECTIVE THAN STANDARD THERAPIES!
Time of Update: 2020-05-28
May 26, 2020 / Biovalley BIOON /- A major clinical trial reported that a drug that has been approved to treat breast cancer and ovarian cancer is more effective than targeted hormone therapy in
-
A new breakthrough! Olapari is FDA approved to treat metastatic anti-aggressive prostate cancer with HRR gene mutation
Time of Update: 2020-05-20
2020 May 20, AstraZeneca and Merck today announced that Li Puzhuo ® (English trade name: Lynparza, common name: Ola Palley) has been approved in the United States for treatment homologous recombina
-
EGFR-MET bispecific antibody! Johnson amivantamab treatment EGFR No. 20 exon insertion of mutant lung cancer (NSCLC) shows lasting remission!
Time of Update: 2020-05-19
2020 May 19 News / BioValley BIOON / - Johnson & Johnson (JNJ) subsidiary Janssen Pharmaceutica Inc today announced the results of Phase II CHRYSALIS study (NCT02609776), which study evaluated the
-
5th lung cancer indication! FDA approves Roche Tecentriq,single-drug first-line treatment PD-L1 high expression NSCLC!
Time of Update: 2020-05-19
May 19, 2020 / PRNewswire BIOON/--Roche's Gene Tekannounc recently announced that the U.S Food and Drug Administration (FDA) has approved the anti-PD-L1 therapy Tecentriq (Special Oddity, generic n
-
Target BCMA and CD3! Johnson and Johnson announces the first clinical data for the treatment of recurrent/difficult multiple myeloma by bispecific antibody teclistamab, ORR- 67%!
Time of Update: 2020-05-19
2020 May 19 News / BioValley BIOON / - Johnson & Johnson (JNJ) subsidiary Janssen Pharmaceutica Inc today reported its first teclistamab (JNJ-64007957, JNJ- 7957) I dose escalation results of hum
-
Cell Rep: Unleash Molecular "Brake" to Promote Cancer Immunotherapy
Time of Update: 2020-05-19
2020 May 19 News / BioValley BIOON / --- according to a new study recently published in the "CellReports" magazine, miRNA molecules can act as a "brake" regulate the activity of immune cells , whic
-
Lung cancer's first HER2-guided therapy! AstraZeneca/First Three-Target Drug Enhertu is awarded the third breakthrough drug by the FDA!
Time of Update: 2020-05-19
2020 May 19 News / BioValley BIOON / - AstraZeneca (AstraZeneca) and the first three-partner total pharmaceutical (DaiichiSankyo) have jointly announced that the US food and Drug Administration
-
Lymphoma (cHL) immunotherapy! Mercadon Keytruda (Korida) Head-to-head Phase III trial efficacy beat swata Adcetris (Ansili)!
Time of Update: 2020-05-19
19 May 2020 /PRNewswire BIOON/-Merck and Co recently announced the results of the anti-PD-1 therapy Keytruda (Creeda, generic name: Pembrolizumab, Pablo Bezumab) treatment of classic Hodgkin's lymph
-
Wuhan team finds 3 new crown death markers, establishes prediction model accuracy of more than 90%
Time of Update: 2020-05-18
quickly and accurately assess the condition of patients is extremely important for the new crown pneumonia Local time on May 14, Tongji Hospital, Tongji Medical College, Huazhong University of S
-
Redefining the first-line treatment of lung cancer! BMS Odivo® (Navuriu mono-resistance) combined with Ipilu mono-resistance approved by the U.S. FDA to treat patients with metastatic non-small cell lung cancer (PD-L1 s1%)
Time of Update: 2020-05-18
, The U.S Food and Drug Administration (FDA) has approved Odivo (Navuliyu monoantigen, 3 mg/kg) in combination with Epiwood monoantigen (1mg/kg, intravenous lygivation) for first-line treatment of me
-
First-line immunotherapy for lung cancer! BMS star immune combination Opdivo-Yervoy has been approved by the FDA for the fifth indication, significantly extending survival!
Time of Update: 2020-05-17
2020 May 17 News / BioValley BIOON / - Bristol-Myers Squibb (BMS) announced today that the US Food and Drug Administration ( FDA ) has approved anti-PD-1 therapy Opdivo (Ou Diwo, generic name: ni
